Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

CNTX
Context Therapeutics Inc. Common Stock
stock NASDAQ

At Close
Nov 17, 2025 3:59:30 PM EST
1.16USD-0.431%(-0.01)191,398
1.14Bid   1.16Ask   0.02Spread
Pre-market
Nov 17, 2025 8:51:30 AM EST
1.18USD+1.724%(+0.02)100
After-hours
Nov 14, 2025 4:44:30 PM EST
1.16USD-0.846%(-0.01)0
OverviewHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 24, 2022
10:32AM EST  ThinkEquity Initiates Coverage On Context Therapeutics with Buy Rating, Announces Price Target of $10   Benzinga
Jan 5, 2022
04:01PM EST  Context Therapeutics Strengthens Research &   GlobeNewswire Inc
Jan 4, 2022
07:30AM EST  Context Therapeutics Inc. (Context or the Company) (Nasdaq: CNTX), a womens oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers,today announced that Chief Executive Officer Martin Lehr will participate virtually in two investor conferences in January 2022.   GlobeNewswire Inc
Dec 10, 2021
05:21AM EST  Context Therapeutics Shares Up 40% Premarket Co Announced Positive Data Thursday From ONA-XR In Early Breast Cancer   Benzinga
Dec 9, 2021
10:01PM EST  Context Therapeutics Shares Spike Higher; Co Announces Data From ONA-XR In Early Breast Cancer; Says ONA-XR Decreased Proliferation In Tumors With High PR+ At Baseline In Early Breast Cancer   Benzinga
06:00PM EST  Data demonstrated ONA-XR decreased proliferation in tumors with high PR+ at baseline in early breast cancer   GlobeNewswire Inc
Dec 8, 2021
08:19AM EST  The Daily Biotech Pulse: Valneva Strikes Deal To Supply COVID Vaccine to Bahrain, TherapeuticsMD & Amneal Settle Patent Lawsuit, Reata Awaits Adcom   Benzinga
Dec 6, 2021
04:45PM EST  Context Therapeutics Inc. Announces Closing of $31.25 Million   GlobeNewswire Inc
06:07AM EST  The Week Ahead In Biotech (Dec. 6-Dec. 11): Dar FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More   Benzinga
Dec 2, 2021
04:04PM EST  Context Therapeutics Q3 2021 Cash And Cash Equivalents $400K   Benzinga
04:01PM EST  Context Therapeutics Reports Third Quarter 2021   GlobeNewswire Inc
02:51PM EST  Mid-Afternoon Market Update: Dow Jumps Over 600 Points; Kroger Shares Spike Higher   Benzinga
12:12PM EST  Mid-Day Market Update: Express Rises Following Q3 Earnings; Context Therapeutics Shares Plummet   Benzinga
10:25AM EST  Mid-Morning Market Update: Markets Mostly Higher; Dollar General Posts Upbeat Q3 Earnings   Benzinga
Dec 1, 2021
06:30PM EST  Context Therapeutics Inc. Announces $31.25 Million Private Placement   GlobeNewswire Inc
Nov 19, 2021
09:03AM EST  Context Therapeutics Reports Will Present Clinical Data On ONA-XR In Breast Cancer At San Antonio Breast Cancer Symposium Dec. 8, 9   Benzinga
09:00AM EST  Context Therapeutics to Present Clinical Data on   GlobeNewswire Inc
Nov 15, 2021
10:37AM EST  The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More   Benzinga
Nov 2, 2021
10:54AM EDT  The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US   Benzinga
10:22AM EDT  Context Therapeutics Appoints Jennifer Minai-Azary CFO   Benzinga
Nov 1, 2021
04:02PM EDT  Context Therapeutics Inc. (Nasdaq: CNTX), a womens oncology company developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers, today announced the appointment of Jennifer Minai-Azary as Chief Financial Officer and the prior appointment, in April 2021, of Alex Levit as Chief Legal Officer.   GlobeNewswire Inc
Oct 27, 2021
07:35AM EDT  Context Therapeutics, Wisconsin Oncology Network Report First Patient Dosed In Phase 2 Trial Of ONA-XR In Metastatic Breast Cancer   Benzinga
07:30AM EDT  Context Therapeutics and Wisconsin Oncology Network   GlobeNewswire Inc
Oct 24, 2021
11:45AM EDT  The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More   Benzinga
Oct 22, 2021
04:05PM EDT  Context Therapeutics Announces Closing of Initial   GlobeNewswire Inc
Oct 20, 2021
11:28AM EDT  Context Therapeutics Shares Open For Trade At $4.44; IPO Priced $5/Share   Benzinga
10:52AM EDT  IPOs For Today, Oct. 20, 2021   Benzinga
10:45AM EDT  Context Therapeutics Shares Opened For Quote At 10:35 a.m. EDT, Expected To Open For Trade After 10:45 a.m. EDT; IPO Priced $5/Share   Benzinga
Oct 19, 2021
10:23PM EDT  Context Therapeutics Prices IPO Of 5 Mln Shares At $5.00/shr   RTTNews
07:14PM EDT  Context Therapeutics Announces Pricing of Initial   GlobeNewswire Inc
Jul 27, 2021
11:13AM EDT  The IPO Market Is On Fire With Another Record Week Ahead   Benzinga
Oct 29, 2020
07:30AM EDT  Centrexion Therapeutics Corporation, a biotechnology company focused on developing and commercializing non-opioid, non-addictive chronic pain drugs and in-licensing undervalued mid-stage drug candidates across multiple target therapeutic areas, today announced that it has raised $40.5 million of cash via:   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-5
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC